title: Capecitabine and the Risk of Fingerprint Loss.
authors: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
authors: Leni
authors: L
authors: van Doorn
authors: Regional Criminal Investigations Division, National Police, The Hague, the Netherlands.
authors: Sebastiaan
authors: S
authors: Veelenturf
authors: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands3Apotheek Haagse Ziekenhuizen/HagaZiekenhuis, The Hague, the Netherlands.
authors: Lisette
authors: L
authors: Binkhorst
authors: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
authors: Sander
authors: S
authors: Bins
authors: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
authors: Ron
authors: R
authors: Mathijssen
mesh_terms: D000069287:Capecitabine / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003878:Dermatoglyphics; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D060831:Hand-Foot Syndrome / Q000209:etiology / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012873:Skin Diseases, Genetic / Q000139:chemically induced / Q000473:pathology*
chemical_list: D000069287:Capecitabine; D005472:Fluorouracil